AMRI dd-sheet. $7.79

stockcharts.com

For more than 20 years, as Albany Molecular Research Inc. (AMRI), we have provided fully integrated drug discovery, development and manufacturing services – all while adapting to the rapidly changing needs of our customers within the pharmaceutical, biotechnology and related industries.

10/31/12  Outstanding Shares 30,924,480 excluding treasury shares of 5,411,372

Major Stock Holders. Inc Mutual Funds.

2/13/13 AMRI and Codexis Announce Technology Collaboration

2/12/13 Net income under U.S. GAAP was $1.9 million , or $0.07 per basic and diluted share, in the fourth quarter of 2012, compared to a U.S. GAAP net loss of $(24.4) million , or $(0.81) per basic and diluted share for the fourth quarter of 2011.

12/6/12 AMRI Extends Long Term Supply Relationship with GE Healthcare

11/30/12 Further actions to expand and better integrate its in vitro biology services with its total drug discovery service platform.

cGMP Manufacturing

Aseptic Fill & Finish You Tube.

http://www.youtube.com/watch?v=W5u7ubc28g4&am...r_embedded

Developement

Drug Discovery Platform at AMRI